Search all trials

Find therapies in clinical trials near you – page 2

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Myelofibrosis+1

Recruiting

Registered drug

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Ruxolitinib

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Registered drugNo placebo

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Pulmonary hypertension

Recruiting

Investigational

A study to evaluate the effectiveness of levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Levosimendan

Contact Research Centre

Breast cancer+4

Recruiting

Registered drugNo placebo

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Elacestrant

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Registered drugNo placebo

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Hepatitis D

Recruiting

Registered drugNo placebo

A study comparing brelovitug to bulevirtide for treating chronic hepatitis delta infection in patients currently receiving bulevirtide

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Bjt-778

Contact Research Centre

Follicle centre lymphoma follicular grade I, II - III

Recruiting

Registered drugNo placebo

A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Registered drug

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cytarabine

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Registered drugNo placebo

A Study of Amivantamab With Carboplatin and Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Amivantamab

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Registered drugNo placebo

A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:BGB-16673

Contact Research Centre

Prostate cancer

Recruiting

Registered drugNo placebo

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate

Contact Research Centre

Breast cancer+1

Recruiting

Registered drugNo placebo

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Find therapies in clinical trials near you – page 2

95 trials match your criteria

Myelofibrosis+1

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Non-small cell lung cancer+1

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Pulmonary hypertension

A study to evaluate the effectiveness of levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.

Breast cancer+4

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Colorectal cancer metastatic

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Hepatitis D

A study comparing brelovitug to bulevirtide for treating chronic hepatitis delta infection in patients currently receiving bulevirtide

Follicle centre lymphoma follicular grade I, II - III

A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

Acute myeloid leukaemia

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Squamous cell carcinoma of head and neck

A Study of Amivantamab With Carboplatin and Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Chronic lymphocytic leukaemia+1

A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Prostate cancer

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Breast cancer+1

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.